Try it
Pharmacology · Sex hormone modulators: aromatase inhibitors
Sample itemWhy is an aromatase inhibitor such as anastrozole used alone only in postmenopausal women and not in premenopausal women with ER-positive breast cancer?
Original practice item, not a recalled exam question. Nothing here is recorded.
The answer and the reasoning
C. Falling oestrogen removes feedback inhibition, raising gonadotropins and ovarian aromatase activity
In postmenopausal women oestrogen comes mainly from peripheral aromatisation of adrenal androgens, which anastrozole blocks. In premenopausal women, lowering oestrogen removes negative feedback and raises FSH and LH, driving the ovary to increase aromatase and androgen substrate, which overcomes the inhibition. Ovarian suppression is needed alongside it. Bone loss is a major adverse effect.
Option by option
A. It is inactivated by high progesterone levels
Progesterone levels do not inactivate the drug.
B. It is metabolised too rapidly by the premenopausal liver
There is no accelerated hepatic clearance in premenopausal women.
C. Falling oestrogen removes feedback inhibition, raising gonadotropins and ovarian aromatase activity (correct)
Correct. Loss of feedback increases gonadotropin drive and ovarian oestrogen output.
D. It acts only on ovarian aromatase and not on peripheral aromatase
Aromatase inhibitors block the enzyme in all tissues, including peripheral sites.
Source note: Original NextPrep sample item — pending expert review. This item is original practice material awaiting independent expert review, so confirm important facts in a standard textbook.
More Pharmacology questions
- Emergency drugsA patient develops stridor, wheeze and hypotension minutes after an injection. What is t…
- AntiepilepticsWhat is the preferred first-line drug for a patient in generalised convulsive status epi…
- AntimicrobialsWhich drug can cause a disulfiram-like reaction when taken with alcohol?
- AntiepilepticsWhich drug is preferred for uncomplicated childhood absence seizures?